AsiDNA

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with no drug-related serious adverse event and no dose-limiting toxicity Company intends to expand AsiDNA™ clinical program in combination in targeted indications as soon as H1 2019 Company to host a conference call for analysts and investors today at 5.30 pm…read more →

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at…read more →

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant to olaparib AsiDNA™ combined with various PARP inhibitors prevented the occurrence of resistance and reversed…read more →

Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor

First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted in three internationally-renowned clinical centers Interim results expected in second half of 2018 Paris (France), April 24, 2018 – 06:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative…read more →

Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting

Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced the presentation of two preclinical study abstracts highlighting AsiDNA™, the Company’s first-in-class DNA break repair inhibitor candidate, at the upcoming…read more →

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent to be granted in Europe on several products including AsiDNA™ as such until 2031, with potential extension to 2036 Onxeo’s intellectual property for DNA-targeting technologies, products and combinations now protected by 10 patent families worldwide   Paris (France), January 25,…read more →

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its robust development programs for AsiDNA™ and belinostat, supported by recent promising combination data and preliminary clinical data expected in 2018 Company is well-financed into early 2020, with the resources to support the current clinical development plan Paris (France), October 2, 2017 – 07:00…read more →

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) This synergy is particularly high for the combination of  its two proprietary assets, AsiDNA™ and belinostat, Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application   Paris (France), September 28, 2017 –…read more →

Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration

Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 2017 – 07h30 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced…read more →

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark…read more →

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), January 31, 2017 – 08:30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, and the Institut Curie, a…read more →

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class product derived directly from this technology Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that…read more →

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence until 2027 Any product including this specific DNA sequence will be within the scope of this patent AsiDNA™’s intellectual property will now be protected by 8 complementary patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen:…read more →

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced results from a preclinical study demonstrating that the synergistic effect of its lead signal-interfering DNA product candidate AsiDNA™ in combination with various products in the PARP (PolyADP-Ribose Polymerase) inhibitor…read more →

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031 // DANISH TRANSLATION: Onxeo modtager “Notice of Allowance” fra de amerikanske patentmyndigheder for det primære AsiDNA™ patent, hvilket forlænger patentbeskyttelsen i USA indtil 2031

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair signal interfering technology and products protected by 8 patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapies, today…read more →

12